Familial Chylomicronemia Syndrome (FCS)Early Phase 1NCT07176923
CS-121 APOC3 Base Editing in FCS
A Early Phase 1 study testing CS-121 in people with Familial Chylomicronemia Syndrome (FCS), run by CorrectSequence Therapeutics Co., Ltd at 1 site in China.
Trial summary
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia… Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Familial Chylomicronemia Syndrome (FCS)
- What is being tested?
- CS-121
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteChina
- Study dates
- 15 Oct 2025to Dec 2026
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female aged 18 to 55 years (inclusive) at the time of signing informed consent.
- On regular standard therapy with good compliance, but fasting triglyceride (TG) levels have not been consistently reduced below 10 mmol/L (880 mg/dL); i.e., before screening, there must be records of at least three separate fasting TG values >10 mmol/L (880 mg/dL), or the participant is intolerant to standard therapy.
- North American Familial Chylomicronemia Syndrome (NAFCS) score ≥45
- Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol, such as dietary guidance and intake restrictions.
- Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screening and be willing to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) during the study. Male participants with reproductive potential must agree to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) throughout the entire post-dose observation period; males without reproductive potential must provide supporting medical history (e.g., post-vasectomy).
Who cannot join
- Currently participating in another interventional clinical study, or last use of another investigational product with a washout period of less than 5 half-lives or 30 days (whichever is longer).
- Use of APOC3-targeted antisense oligonucleotides (ASO) or siRNA lipid-lowering agents within 6 months prior to dosing.
- History of acute pancreatitis within 3 months before dosing.
- History of acute coronary syndrome (ACS) within 6 months before dosing, such as myocardial infarction or unstable angina, or prior coronary revascularization (e.g., coronary artery bypass grafting, angioplasty, or stent implantation).
- In the investigator's judgment, receipt of major surgery within 3 months before dosing that would make the participant unsuitable for this study drug or unable to tolerate possible cytokine-release events.
- Any of the following laboratory abnormalities at screening:
Show all 12Show fewer
- ALT or AST ≥3 × ULN Total bilirubin ≥1.5 × ULN eGFR <30 mL/min/1.73 m² Random urine albumin-to-creatinine ratio (UACR) >30 mg/g LDL-C >130 mg/dL (3.4 mmol/L) HbA1c ≥9%
- Coagulation abnormalities deemed by the investigator to make CS-121 administration unsuitable.
- Positive at screening for HBsAg, HCV antibody and RNA, HIV, or Treponema pallidum (syphilis).
- Known major organ disease, psychiatric disorders, Cushing's syndrome, or malignancy that, in the investigator's judgment, would make the participant unsuitable for the study or unable to tolerate possible cytokine-release-like events.
- Concomitant medications or treatments judged by the investigator to affect lipid metabolism, hepatic or renal function, or coagulation, or to interfere with the evaluation of study drug efficacy, including but not limited to: systemic glucocorticoids, anabolic steroids, antiretroviral agents used within 4 weeks prior to dosing, plasma exchange, blood donation, or blood loss >200 mL.
- Planning pregnancy, currently pregnant, or breastfeeding.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui
Huan Zhou, +8613665527160, zhouhuanbest@vip.163.com
Huan Zhou
About this study
Official title: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Adults With Familial Chylomicronemia Syndrome
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Read the detailed description
Familial chylomicronemia syndrome (FCS) is a rare, autosomal recessive lipid metabolism disorder characterized by impaired clearance of triglyceride-rich lipoproteins due to deficiencies in lipoprotein lipase or its cofactors. Patients experience severe hypertriglyceridemia, recurrent episodes of acute pancreatitis, abdominal pain, and other complications that significantly reduce quality of life and may be life-threatening. Despite strict dietary restrictions and conventional lipid-lowering therapies, many patients fail to achieve adequate triglyceride control, highlighting a major unmet medical need.
CS-121 is an investigational, in vivo base editing therapy delivered by lipid nanoparticles (LNPs) targeting the APOC3 gene in the liver. By introducing precise base edits at specific APOC3 loci, CS-121 is intended to mimic naturally occurring protective mutations that reduce ApoC3 expression, thereby restoring triglyceride clearance pathways and lowering pancreatitis risk. Preclinical studies in transgenic mouse and non-human primate models demonstrated dose-dependent APOC3 editing, reductions in serum ApoC3 protein and triglyceride levels, and acceptable safety profiles, supporting advancement into first-in-human evaluation.
This Phase I study uses an adaptive, dose-escalation design to investigate multiple dose levels of CS-121 in adults with genetically and clinically confirmed FCS. The design incorporates dynamic dose adjustment based on emerging safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, consistent with regulatory guidance for rare disease trials.
Participants will undergo screening to confirm eligibility, including fasting triglyceride measurements, North American FCS score (NAFCS), genetic and laboratory testing, and imaging studies. Eligible participants will receive a single intravenous infusion of CS-121 and will be observed in-clinic immediately post-dose for early safety monitoring. Extended follow-up visits will be conducted for up to 10 months, with evaluations of clinical safety parameters, ApoC3 protein and triglyceride levels, drug exposure (sgRNA/mRNA), and exploratory endpoints such as pancreatitis incidence and imaging of hepatic lipid accumulation.
The study is designed to establish a dose range, identify an optimal biological dose (OBD), and provide first-in-human safety, tolerability, PK, and PD data for CS-121 in FCS. Findings from this trial will inform the future development of base editing therapies in severe hypertriglyceridemia and related rare metabolic disorders.
- Conditions
- Familial Chylomicronemia Syndrome (FCS)
- Being tested
- CS-121
- Keywords
- Familial Chylomicronemia Syndrome (FCS), Severe Hypertriglyceridemia, Acute Pancreatitis, Apolipoprotein C3 (APOC3), In Vivo Base Editing, Lipid Nanoparticles (LNP), Gene Editing Therapy, First-in-Human Study, Rare Metabolic Disorder
- Medical subject headings
- Familial hyperchylomicronemia syndrome, Hypertriglyceridemia, Pancreatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CS-121Biological
CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 protein expression and serum triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
| Study group | Role | What they receive |
|---|---|---|
| Single Low Dose CS-121 | Experimental | Participants in this arm will receive a single low dose of CS-121. Receives: Biological: CS-121 |
| Single Middle Dose CS-121 | Experimental | Participants in this arm will receive a single middle dose of CS-121. Receives: Biological: CS-121 |
| Single High Dose CS-121 | Experimental | Participants in this arm will receive a single high dose of CS-121. Receives: Biological: CS-121 |
| Single Lower Dose 1 of CS-121 | Experimental | Participants in this arm will receive a single lower dose 1 of CS-121. Receives: Biological: CS-121 |
| Single Lower Dose 2 of CS-121 | Experimental | Participants in this arm will receive a single lower dose 2 of CS-121. Receives: Biological: CS-121 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment-Emergent Adverse Events (TEAEs)
Incidence, nature, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and abnormalities in clinical symptoms, vital signs, physical examinations, laboratory tests, and electrocardiograms (ECGs). Severity will be graded according to NCI CTCAE version 5.0.
Measured: From the start of dosing through approximately 10 months of follow-up
Dose-Limiting Toxicities (DLTs)
Within 14 days after CS-121 infusion
Measured: Number and type of dose-limiting toxicities (DLTs), defined as CTCAE grade ≥3 adverse events considered possibly, probably, or definitely related to CS-121 and persisting ≥7 days, or other adverse events/laboratory abnormalities that lead to suspension o
Secondary outcomes (5)
Change from Baseline in Fasting Serum Triglycerides (TG)
Absolute and relative change in fasting serum triglyceride levels compared with baseline values.
Measured: Baseline through approximately 10 months after dosing
Change from Baseline in Serum ApoC3 Protein Levels
Absolute and relative change in serum ApoC3 protein concentrations compared with baseline values.
Measured: Baseline through approximately 10 months after dosing
Peak Concentration (Cmax) of CS-121 Components
Maximum observed concentration of CS-121 components following intravenous infusion.
Measured: From dosing through approximately 1 month after infusion.
Time to Maximum Concentration (Tmax) of CS-121 Components
Time to reach maximum observed concentration of CS-121 components following intravenous infusion
Measured: From dosing through approximately 1 month after infusion
Area Under the Curve (AUC) of CS-121 Components
Area under the Curve of CS-121 components to characterize systemic exposure
Measured: From dosing through approximately 1 month after infusion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2025
- Study start15 Oct 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Familial Chylomicronemia Syndrome (FCS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- About 3-15 participants with NAFCS ≥45 and fasting triglycerides ≥10 mmol/L will be enrolled. The study follows an adaptive design with three ascending dose levels and up to two de-escalation cohorts if needed. Each cohort includes 1-3 participants; escalation proceeds after ≥14 days of safety, PK, and PD review. A single intravenous infusion of CS-121 is given, followed by 5 days of inpatient monitoring and \~10 months of follow-up to assess safety, tolerability, PK, PD, and exploratory efficacy including triglyceride reduction and pancreatitis incidence.
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CorrectSequence Therapeutics Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- The First Affiliated Hospital of Anhui Medical University
- Responsible party
- Sponsor
- Investigators
- YALIANG LI, Study director, CorrectSequence Therapeutics (Shanghai) Co., Ltd
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07176923
- Sponsor's protocol ID
- CS-121-01
- Status last verified
- Feb 2026
- First submitted
- 30 Aug 2025
- Last updated
- 11 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Adults With Familial Chylomicronemia Syndrome
- ClinicalTrials.gov ID
- NCT07176923
- Acronym / sponsor ID
- CS-121-01
- Conditions
- Familial Chylomicronemia Syndrome (FCS)
- Keywords
- Familial Chylomicronemia Syndrome (FCS), Severe Hypertriglyceridemia, Acute Pancreatitis, Apolipoprotein C3 (APOC3), In Vivo Base Editing, Lipid Nanoparticles (LNP), Gene Editing Therapy, First-in-Human Study
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- CorrectSequence Therapeutics Co., LtdIndustry (pharma, biotech, devices)
- Collaborators
- The First Affiliated Hospital of Anhui Medical University
- Study start
- 15 Oct 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 16 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Detailed description
Familial chylomicronemia syndrome (FCS) is a rare, autosomal recessive lipid metabolism disorder characterized by impaired clearance of triglyceride-rich lipoproteins due to deficiencies in lipoprotein lipase or its cofactors. Patients experience severe hypertriglyceridemia, recurrent episodes of acute pancreatitis, abdominal pain, and other complications that significantly reduce quality of life and may be life-threatening. Despite strict dietary restrictions and conventional lipid-lowering therapies, many patients fail to achieve adequate triglyceride control, highlighting a major unmet medical need.
CS-121 is an investigational, in vivo base editing therapy delivered by lipid nanoparticles (LNPs) targeting the APOC3 gene in the liver. By introducing precise base edits at specific APOC3 loci, CS-121 is intended to mimic naturally occurring protective mutations that reduce ApoC3 expression, thereby restoring triglyceride clearance pathways and lowering pancreatitis risk. Preclinical studies in transgenic mouse and non-human primate models demonstrated dose-dependent APOC3 editing, reductions in serum ApoC3 protein and triglyceride levels, and acceptable safety profiles, supporting advancement into first-in-human evaluation.
This Phase I study uses an adaptive, dose-escalation design to investigate multiple dose levels of CS-121 in adults with genetically and clinically confirmed FCS. The design incorporates dynamic dose adjustment based on emerging safety, pharmacokinetic (PK), and pharmacodynamic (PD) data, consistent with regulatory guidance for rare disease trials.
Participants will undergo screening to confirm eligibility, including fasting triglyceride measurements, North American FCS score (NAFCS), genetic and laboratory testing, and imaging studies. Eligible participants will receive a single intravenous infusion of CS-121 and will be observed in-clinic immediately post-dose for early safety monitoring. Extended follow-up visits will be conducted for up to 10 months, with evaluations of clinical safety parameters, ApoC3 protein and triglyceride levels, drug exposure (sgRNA/mRNA), and exploratory endpoints such as pancreatitis incidence and imaging of hepatic lipid accumulation.
The study is designed to establish a dose range, identify an optimal biological dose (OBD), and provide first-in-human safety, tolerability, PK, and PD data for CS-121 in FCS. Findings from this trial will inform the future development of base editing therapies in severe hypertriglyceridemia and related rare metabolic disorders.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 5
- Model description
- About 3-15 participants with NAFCS ≥45 and fasting triglycerides ≥10 mmol/L will be enrolled. The study follows an adaptive design with three ascending dose levels and up to two de-escalation cohorts if needed. Each cohort includes 1-3 participants; escalation proceeds after ≥14 days of safety, PK, and PD review. A single intravenous infusion of CS-121 is given, followed by 5 days of inpatient monitoring and ~10 months of follow-up to assess safety, tolerability, PK, PD, and exploratory efficacy including triglyceride reduction and pancreatitis incidence.
| Arm | Type | Receives |
|---|---|---|
| Single Low Dose CS-121 | Experimental | Biological: CS-121Participants in this arm will receive a single low dose of CS-121. |
| Single Middle Dose CS-121 | Experimental | Biological: CS-121Participants in this arm will receive a single middle dose of CS-121. |
| Single High Dose CS-121 | Experimental | Biological: CS-121Participants in this arm will receive a single high dose of CS-121. |
| Single Lower Dose 1 of CS-121 | Experimental | Biological: CS-121Participants in this arm will receive a single lower dose 1 of CS-121. |
| Single Lower Dose 2 of CS-121 | Experimental | Biological: CS-121Participants in this arm will receive a single lower dose 2 of CS-121. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male or female aged 18 to 55 years (inclusive) at the time of signing informed consent.
- On regular standard therapy with good compliance, but fasting triglyceride (TG) levels have not been consistently reduced below 10 mmol/L (880 mg/dL); i.e., before screening, there must be records of at least three separate fasting TG values >10 mmol/L (880 mg/dL), or the participant is intolerant to standard therapy.
- North American Familial Chylomicronemia Syndrome (NAFCS) score ≥45
- Able to sign informed consent and comply with the requirements and restrictions specified in the informed consent form and the protocol, such as dietary guidance and intake restrictions.
- Female participants must meet one of the following: be not of childbearing potential (e.g., documented hysterectomy, bilateral salpingectomy/sterilization, or ≥1 year postmenopausal); or, if of childbearing potential, have a negative pregnancy test at screening and be willing to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) during the study. Male participants with reproductive potential must agree to use strict and effective contraception (e.g., abstinence, pharmacologic, or barrier methods) throughout the entire post-dose observation period; males without reproductive potential must provide supporting medical history (e.g., post-vasectomy).
Key exclusion criteria (12 listed)
- Currently participating in another interventional clinical study, or last use of another investigational product with a washout period of less than 5 half-lives or 30 days (whichever is longer).
- Use of APOC3-targeted antisense oligonucleotides (ASO) or siRNA lipid-lowering agents within 6 months prior to dosing.
- History of acute pancreatitis within 3 months before dosing.
- History of acute coronary syndrome (ACS) within 6 months before dosing, such as myocardial infarction or unstable angina, or prior coronary revascularization (e.g., coronary artery bypass grafting, angioplasty, or stent implantation).
- In the investigator's judgment, receipt of major surgery within 3 months before dosing that would make the participant unsuitable for this study drug or unable to tolerate possible cytokine-release events.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CS-121CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 protein expression and serum triglyceride levels in adults with familial chylomicronemia syndrome (FCS). | Biological | Single High Dose CS-121, Single Low Dose CS-121, Single Lower Dose 1 of CS-121, Single Lower Dose 2 of CS-121, Single Middle Dose CS-121 |
Primary outcome
Treatment-Emergent Adverse Events (TEAEs)
Time frame: From the start of dosing through approximately 10 months of follow-up
Incidence, nature, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and abnormalities in clinical symptoms, vital signs, physical examinations, laboratory tests, and electrocardiograms (ECGs). Severity will be graded according to NCI CTCAE version 5.0.
Dose-Limiting Toxicities (DLTs)
Time frame: Number and type of dose-limiting toxicities (DLTs), defined as CTCAE grade ≥3 adverse events considered possibly, probably, or definitely related to CS-121 and persisting ≥7 days, or other adverse events/laboratory abnormalities that lead to suspension o
Within 14 days after CS-121 infusion
5 secondary outcomes
Change from Baseline in Fasting Serum Triglycerides (TG)
Time frame: Baseline through approximately 10 months after dosing
Change from Baseline in Serum ApoC3 Protein Levels
Time frame: Baseline through approximately 10 months after dosing
Peak Concentration (Cmax) of CS-121 Components
Time frame: From dosing through approximately 1 month after infusion.
Time to Maximum Concentration (Tmax) of CS-121 Components
Time frame: From dosing through approximately 1 month after infusion
Area Under the Curve (AUC) of CS-121 Components
Time frame: From dosing through approximately 1 month after infusion.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Familial Chylomicronemia Syndrome (FCS)
RecruitingPhase 3
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Familial Chylomicronemia Syndrome
Active, not recruitingPhase 3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Familial Chylomicronemia Syndrome
Active, not recruitingPhase 3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Familial Chylomicronemia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
YALIANG LI study director
CorrectSequence Therapeutics (Shanghai) Co., Ltd
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing CS-121 in people with Familial Chylomicronemia Syndrome (FCS), run by CorrectSequence Therapeutics Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yaliang Li (+8618621046122, yaliang.li@correctsequence.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment-Emergent Adverse Events (TEAEs) (time frame: From the start of dosing through approximately 10 months of follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.